Article
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Oct 2025
Sun Fangdi, Banwait Mandeep K, Singhal Surbhi, Herrmann Amanda, Piotrowska Zofia, Yun Karen, Bazhenova Lyudmila, Ullah Ayman T, Guo Emily W, Wakelee Heather A, Neal Joel W, Das Millie S, Ramchandran Kavitha J, Roy Mohana, Diehn Maximilian, Myall Nathaniel J
Abstract excerpt
PURPOSE: Until recently, osimertinib was the preferred first-line therapy for nearly all patients with EGFR-mutated advanced NSCLC. However, with approval of the FLAURA2 and MARIPOSA regimens, identifying molecular or clinical factors that confer higher risk for inferior outcomes to first-line osimertinib may better inform upfront treatment selection for newly-diagnosed patients. METHODS: This real-world,...
Topics
Join the communities discussing this publication.